Lower Drug Pricing Key to Fix for Industry’s Image, Says AHF Report on Forbes.com says ‘Pharma's Reputation Continues to Suffer,’ and a recent industry survey shows pharma’s reputation ranks at the bottom of all health care industries due to ‘a lack of fair pricing policies leading to unseemly profits,’–AHF says price reductions are key to repairing pharma’s image While Gilead Sciences (GILD) ranked second in the Patient View Quarterly survey, poor record of price hikes for lifesaving AIDS drugs and price gouging of taxpayer-funded drug programs tarnish company Business Wire WASHINGTON -- January 18, 2013 In response to a Forbes.com story entitled “Pharma's Reputation Continues to Suffer -- What Can Be Done To Fix It?” and recent Patient View Quarterly survey showing the pharmaceutical industry’s reputation ranks at the bottom of all health care industries, leading global nonprofit AIDS Healthcare Foundation (AHF) contends that the key to repairing the drug industry’s poor reputation is to change its policy of gouging prices for medicines, including those used to treat HIV/AIDS. According to the Patient View survey, as reported by Forbes.com, the leading cause of discontent with the pharmaceutical industry is, “a lack of fair pricing policies leading to unseemly profits.” The survey found industry also received a ‘poor’ rating on “Acting with integrity.” “Pharma should hear the message loud and clear; its policy of gouging patients over their health is backfiring. The fact that a company like Gilead Sciences, a company whose business model is to gouge government programs and people with HIV/AIDS in order to maximize profits, is the best pharma has to offer clearly shows far this industry has fallen,” said Michael Weinstein, President of AIDS Healthcare Foundation. Stribild, Gilead’s four-in-one combination pill that was approved by the Food and Drug Administration in September of last year, is the most expensive AIDS first line treatment on the market today at $28,500 per patient, per year, which was 35% higher than the price of their best-selling treatment at that time and is more than most HIV/AIDS patients earn annually. Already this year, on January 1, Gilead raised the prices of four key AIDS medications by an average of 6%, including the price of Atripla, its best-selling three-in-one combination treatment, the price of which was increased by 6.9% to a Whole Acquisition Cost (WAC) of $1,878.23 per patient, per month. The other three HIV/AIDS medications that saw price hikes are Complera, which was raised by 5.8% to a WAC of $1,936.53; Emtriva, by 5.5% to a WAC of $478.45; and Viread, by 6% to a WAC of $771.39. “If pharma truly cares about patients—its customers—the industry as a whole should dramatically change its pricing policies,” added Weinstein. About AIDS Healthcare Foundation AIDS Healthcare Foundation (AHF), the largest global AIDS organization, currently provides medical care and/or services to nearly 200,000 individuals in 28 countries worldwide in the US, Africa, Latin America/Caribbean, the Asia/Pacific Region and Eastern Europe. To learn more about AHF, please visit our website: www.aidshealth.org, find us on Facebook: www.facebook.com/aidshealth and follow us on Twitter: @aidshealthcare. Contact: AIDS Healthcare Foundation Ged Kenslea Communications Director Los Angeles, CA, USA +1-323-791-5526 [mobile] +1-323-308-1833 [work] email@example.com or Tim Boyd Public Affairs Manager Washington, DC, USA +1-213-590-7375 [mobile] firstname.lastname@example.org
Lower Drug Pricing Key to Fix for Industry’s Image, Says AHF
Press spacebar to pause and continue. Press esc to stop.